2021
DOI: 10.1093/eurjpc/zwab158
|View full text |Cite
|
Sign up to set email alerts
|

A systematic review of mobile health opportunities for atrial fibrillation detection and management

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 14 publications
0
2
0
Order By: Relevance
“…The number of mobile health (mHealth) applications dedicated to heart rate and rhythm monitoring in patients with atrial fibrillation (AF) is constantly increasing with growing numbers of devices and/ or applications with Conformité Européenne (CE) and/or Food and Drug Administration approval. 1,2 Despite high accuracy to detect AF, the efficacy of these mHealth applications is critically determined by the ability and willingness of the patient to use them. The World Health Organization (WHO) has stated that increasing patient adherence to interventions may have a far greater impact on the health of the population than any improvement in specific medical treatments.…”
Section: Introductionmentioning
confidence: 99%
“…The number of mobile health (mHealth) applications dedicated to heart rate and rhythm monitoring in patients with atrial fibrillation (AF) is constantly increasing with growing numbers of devices and/ or applications with Conformité Européenne (CE) and/or Food and Drug Administration approval. 1,2 Despite high accuracy to detect AF, the efficacy of these mHealth applications is critically determined by the ability and willingness of the patient to use them. The World Health Organization (WHO) has stated that increasing patient adherence to interventions may have a far greater impact on the health of the population than any improvement in specific medical treatments.…”
Section: Introductionmentioning
confidence: 99%
“…23 With the expected surge in AF prevalence, 3 24 25 this underlines that a suited screening strategy is needed to identify and treat AF to mitigate mortality, morbidity, and health care expenses. 26 27 But before this, evidence is needed with regard to OAC treatment in subclinical AF. 15 Indeed, screening AF is gaining momentum but remains unknown territory with respect to side effects—that is, early detection and treatment may come with a different risk-benefit trade-off compared with what is known from conventionally diagnosed AF.…”
Section: Discussionmentioning
confidence: 99%